A sulfur-based compound called LASSS appears to protect and supercharge a key protein involved in repairing damaged muscle.

Synlogic, Inc. ("Synlogic") and Caldera Therapeutics, Inc. ("Caldera"), a privately held clinical-stage biotechnology company developing CLD-423, a potential first-in-class TL1A x IL-23p19 bispecific ...

Native-like TNFSF trimers are helping researchers develop more physiologically relevant tools for therapeutic discovery and ...

Orphan designation provides market exclusivity and development benefits in the European Union as both programs advance in global pivotal clinical ...

The Fifth Element IMAX 2026 re-release opens July 26–27 via Fathom Entertainment with real dark energy physics at its back: ...

Reasons to be Cheerful reports on positive news and inspiring stories, highlighting solutions to societal issues and ...

Lioness Season 3 premieres August 2 on Paramount+ with Russia confirmed as the primary antagonist — and the five STEM ...

Unless otherwise noted, all growth rates in this Release refer to same period in prior year. 2. Please see detailed guidance assumptions on page 7. 3. USD millions unless indicated otherwise. Novartis ...

Dead City Season 3 science audit reveals which Walking Dead energy systems hold up: the Croat's methane biogas tanks rest on ...

The centerpiece of the acquisition is Myricx Bio’s novel N-myristoyltransferase inhibitor payload platform, which could help Novartis develop antibody-drug conjugates that can overcome the limitations ...

Spread the loveYou’ve probably heard the buzz about GLP-1 drugs – the injectables like Ozempic and Wegovy that have reshaped ...